Limits...
Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema.

Choi YJ, Oh IK, Oh JR, Huh K - Korean J Ophthalmol (2006)

Bottom Line: Visual acuity and intraocular pressure (IOP) were also measured.Both groups resulted in a significant decrease in central macular thickness (CMT) at 1 month and 3 months post-injection.The posterior subtenon injection of triamcinolone acetonide had a comparable effect to the intravitreal triamcinolone injection and showed a lower risk of elevated IOP.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea.

ABSTRACT

Purpose: To compare the short-term effects of intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema.

Methods: This is a prospective and interventional study. Sixty eyes of 60 patients who had diffuse diabetic macular edema were assigned to receive a single intravitreal injection (4 mg) or a single posterior subtenon injection (40 mg) of triamcinolone acetonide. The central retinal thickness was measured using optical coherent tomography before injection and at 1 and 3 months after injection. Visual acuity and intraocular pressure (IOP) were also measured.

Results: Both intravitreal and posterior subtenon injections of triamcinolone acetonide resulted in significant improvements in visual acuity at 1 month and 3 months after injection. Both groups resulted in a significant decrease in central macular thickness (CMT) at 1 month and 3 months post-injection. IOP in the intravitreal injection group was significantly higher than in the posterior subtenon injection group at 3 months after injection.

Conclusions: The posterior subtenon injection of triamcinolone acetonide had a comparable effect to the intravitreal triamcinolone injection and showed a lower risk of elevated IOP. Posterior subtenon injection of triamcinolone acetonide may be a good alternative for the treatment of diffuse diabetic macular edema.

Show MeSH

Related in: MedlinePlus

Changes in the OCT images of representative patient in the intravitreal and posterior subtenon injection groups. In an eye that underwent intravitreal injection, the marked macular edema (A) decreased substantially and the eye showed virtually normal macular configuration at 3 months (B) after injection. In an eye that underwent posterior subtenon injection, the macular edema (C) also decreased substantially with time, and the eye showed virtually normal macular configuration at 3 months (D) after injection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2908852&req=5

Figure 3: Changes in the OCT images of representative patient in the intravitreal and posterior subtenon injection groups. In an eye that underwent intravitreal injection, the marked macular edema (A) decreased substantially and the eye showed virtually normal macular configuration at 3 months (B) after injection. In an eye that underwent posterior subtenon injection, the macular edema (C) also decreased substantially with time, and the eye showed virtually normal macular configuration at 3 months (D) after injection.

Mentions: The mean baseline CMT was not significantly different between the 2 groups (p=0.461). In both the intravitreal and posterior subtenon injection group, the CMT was significantly decreased through the study (Table 3, Fig. 2). At 3 months after injection, OCT demonstrated a reduction of the mean CMT (intravitreal group: 46.2%, subtenon group: 43.5%). Between the 2 groups, there was no significant difference in the mean CMT change before injection or at 1 month and 3 months after injection. Fig. 3 illustrates the changes in the OCT images of a representative patient in the intravitreal injection group and of a patient in the posterior subtenon injection group.


Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema.

Choi YJ, Oh IK, Oh JR, Huh K - Korean J Ophthalmol (2006)

Changes in the OCT images of representative patient in the intravitreal and posterior subtenon injection groups. In an eye that underwent intravitreal injection, the marked macular edema (A) decreased substantially and the eye showed virtually normal macular configuration at 3 months (B) after injection. In an eye that underwent posterior subtenon injection, the macular edema (C) also decreased substantially with time, and the eye showed virtually normal macular configuration at 3 months (D) after injection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2908852&req=5

Figure 3: Changes in the OCT images of representative patient in the intravitreal and posterior subtenon injection groups. In an eye that underwent intravitreal injection, the marked macular edema (A) decreased substantially and the eye showed virtually normal macular configuration at 3 months (B) after injection. In an eye that underwent posterior subtenon injection, the macular edema (C) also decreased substantially with time, and the eye showed virtually normal macular configuration at 3 months (D) after injection.
Mentions: The mean baseline CMT was not significantly different between the 2 groups (p=0.461). In both the intravitreal and posterior subtenon injection group, the CMT was significantly decreased through the study (Table 3, Fig. 2). At 3 months after injection, OCT demonstrated a reduction of the mean CMT (intravitreal group: 46.2%, subtenon group: 43.5%). Between the 2 groups, there was no significant difference in the mean CMT change before injection or at 1 month and 3 months after injection. Fig. 3 illustrates the changes in the OCT images of a representative patient in the intravitreal injection group and of a patient in the posterior subtenon injection group.

Bottom Line: Visual acuity and intraocular pressure (IOP) were also measured.Both groups resulted in a significant decrease in central macular thickness (CMT) at 1 month and 3 months post-injection.The posterior subtenon injection of triamcinolone acetonide had a comparable effect to the intravitreal triamcinolone injection and showed a lower risk of elevated IOP.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea.

ABSTRACT

Purpose: To compare the short-term effects of intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema.

Methods: This is a prospective and interventional study. Sixty eyes of 60 patients who had diffuse diabetic macular edema were assigned to receive a single intravitreal injection (4 mg) or a single posterior subtenon injection (40 mg) of triamcinolone acetonide. The central retinal thickness was measured using optical coherent tomography before injection and at 1 and 3 months after injection. Visual acuity and intraocular pressure (IOP) were also measured.

Results: Both intravitreal and posterior subtenon injections of triamcinolone acetonide resulted in significant improvements in visual acuity at 1 month and 3 months after injection. Both groups resulted in a significant decrease in central macular thickness (CMT) at 1 month and 3 months post-injection. IOP in the intravitreal injection group was significantly higher than in the posterior subtenon injection group at 3 months after injection.

Conclusions: The posterior subtenon injection of triamcinolone acetonide had a comparable effect to the intravitreal triamcinolone injection and showed a lower risk of elevated IOP. Posterior subtenon injection of triamcinolone acetonide may be a good alternative for the treatment of diffuse diabetic macular edema.

Show MeSH
Related in: MedlinePlus